Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
South Rampart Completes Phase 1 Study and Expands Phase 2 Plans
Details : SRP 3D (diethylamide) is a first-in-class non-opioid analgesic activating pain signaling pathways in the midbrain's periaqueductal grey. It’s in phase 1 trials for acute pain.
Brand Name : SRP 3D
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
South Rampart Pharma Receives U.S. FDA Fast Track Designation for SRP-001 for Acute Pain
Details : SRP-001 is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities and is being developed for the treatment of acute pain.
Brand Name : SRP-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2023
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institute of Health
Deal Size : $1.9 million
Deal Type : Funding
South Rampart Pharma Awarded Second NIH Grant for Commercialization Readiness Pilot Program
Details : The funding Validates the Business Case and Commercial Opportunity of SRP-001 (diethylamide), a first-in-class, novel, non-opioid small molecule analgesic for Acute and Chronic Pain.
Brand Name : SRP-001
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 21, 2023
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institute of Health
Deal Size : $1.9 million
Deal Type : Funding
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SRP-001 (diethylamide) is a novel, non-opioid investigational drug that avoids the liver toxicity associated with acetaminophen, positioned to address the unmet medical need for non-toxic and non-addictive acute and chronic pain therapeutics.
Brand Name : SRP-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 22, 2023
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
South Rampart Pharma Announces Presentation at Arrowhead's 16th Annual Pain Therapeutics Summit
Details : SRP-001 is an AM404 agonist that targets the endocannabinoid (CB1) pain receptors in the brain,for the treatment of acute and chronic pain,is currently being investigated in a two-part, double-blind, placebo-controlled Phase 1 study.
Brand Name : SRP-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2022
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
South Rampart Pharma Announces Late-Breaking Presentation at IASP 2022 World Congress on Pain
Details : SRP-001, is novel acetaminophen analog with unique mechanism of action for its lack of liver toxicity present in acetaminophen. In development to treat acute and other forms of pain, demonstrates that SRP-001 offers a compelling safety profile over avail...
Brand Name : SRP-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2022
Lead Product(s) : Diethylamide
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : National Institutes of Health
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?